Coherence Neuro says its core insight is that cancer, like movement, has an electrical signature: tumors alter electrical signals in surrounding tissue and the nervous system, which the team decodes for detailed disease tracking. It is building neurotechnology and brain-computer interface platforms to both read and modulate cancer in real time. Human device testing has begun, and the funding supports a first chronic human trial in glioblastoma plus preclinical work in pancreatic cancer. New investors include Lux Capital, 8vc, and SV Angel, with hiring in San Francisco and Cambridge, UK. The author argues current treatment feedback is too slow and envisions medicine that continuously learns to improve itself, unlike conventional drugs.

AI summary of the linked source — not editorial content.

Story signal · via Elfa

as of

Market since publication

OPENAI reaction
i
Price change from this article’s publication to 24 hours later (CoinGecko). BTC over the same window is shown so a market-wide move is not mistaken for a reaction to this story. Not advice.
+0.1% 24h after publication

$2,337 → $2,339
BTC −0.5% same window

TradersTrader calls tracked by Elfa · not advice

Positioning · OPENAI

Open72 open positions · 62 long · 10 short

Tracked accounts lean long about 97% of the time, so a long-heavy book is normal, not a signal. As of 20 Oct 23:55 UTC.

Whole crypto market, not this story

Crowding93rd percentile · vs last 28 days, 50 typical
Pulse 24h91/100 · unusualness of new calls, 0–100, 50 typical, higher means more long than usual
Book97.4% long · 11,034 accounts

As of 22 Oct 07:05 UTC.

Social-monitoring data, not investment advice Elfa prices CoinGeckoas of

Explore the topic

Loading related coverage…

Explore the full feed

Comments

Loading comments…